

Table SII. Outcomes of the included studies

Study	Number of subjects		Any sexual adverse effects (%)		Erectile dysfunction (%)		Decreased libido (%)		Difficulty in ejaculation (%)	
	5-ARIs	Placebo	5-ARIs	Placebo	5-ARIs	Placebo	5-ARIs	Placebo	5-ARIs	Placebo
<i>Finasteride 1 mg/day</i>										
Kaufman et al. (1998) (18) and FMPHLSG (2002) (16) ^a	779	774	34 (4.4)	20 (2.6)	11 (1.4)	7 (0.9)	15 (1.9)	10 (1.3)	8 (1.0)	3 (0.4)
Roberts et al. (1999) (19)	117	233	5 (4.3)	8 (6.8)	3 (2.6)	0 (0.0)	2 (1.7)	7 (6.0)	0 (0.0)	1 (0.9)
Leyden et al. (1999) (20)	166	160	3 (1.8)	3 (1.9)	1 (0.6)	0 (0.0)	2 (1.2)	2 (1.3)	0 (0.0)	1 (0.6)
Drake et al. (1999) (6)	37	67	0 (0.0)	3 (4.5)	0 (0.0)	0 (0.0)	0 (0.0)	3 (4.5)	0 (0.0)	0 (0.0)
Neste et al. (2000) (21)	106	106	2 (1.9)	1 (0.9)	NR	NR	NR	NR	NR	NR
Price et al. (2002) (17) and Price et al. (2006) (15) ^b	33	33	1 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.0)	0 (0.0)	0 (0.0)	0 (0.0)
Stough et al. (2002) (22)	9	9	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Whiting et al. (2003) (23) ^c	286	138	25 (8.7)	7 (5.1)	11 (3.8)	1 (0.7)	14 (4.9)	6 (4.3)	8 (2.8)	1 (0.7)
Kawashima et al. (2004) (24)	139	138	4 (2.9)	3 (2.2)	NR	NR	NR	NR	NR	NR
Leavitt et al. (2005) (25)	40	39	2 (5.0)	0 (0.0)	1 (2.5)	0 (0.0)	1 (2.5)	0 (0.0)	0 (0.0)	0 (0.0)
Gubelin et al. (2014) (30) ^e	179	181	24 (13.4)	12 (6.6)	11 (6.1)	7 (3.9)	12 (6.7)	3 (1.7)	7 (3.9)	6 (3.3)
<i>Dutasteride 0.5 mg/day</i>										
Olsen et al. (2006) (26)	68	64	2 (2.9)	5 (7.8)	0 (0.0)	3 (4.7)	1 (1.5)	2 (3.1)	1 (1.5)	0 (0.0)
Stough et al. (2007) (27)	17	17	2 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)	2 (11.8)	0 (0.0)	0 (0.0)	0 (0.0)
Amory et al. (2007) (28) ^d	33	32	6 (18.2)	3 (9.4)	2 (6.1)	2 (6.3)	2 (6.1)	1 (3.1)	1 (3.0)	0 (0.0)
Eun et al. (2010) (29)	73	75	3 (4.1)	3 (4.0)	0 (0.0)	1 (1.3)	3 (4.1)	2 (2.7)	0 (0.0)	1 (1.3)
Gubelin et al. (2014) (30) ^e	184	181	19 (10.3)	12 (6.6)	10 (5.4)	7 (3.9)	9 (4.9)	3 (1.7)	6 (3.3)	6 (3.3)

^aContinuation of the trial of Kaufman et al. (1998) (18). ^bContinuation of the trial of Price et al. (2002) (17). ^{c,d}Owing to the heterogeneity of its study population, this study was omitted from the sensitivity analysis. ^eThe only study in which the safety profile of 1 mg/day finasteride, 0.5 mg/day dutasteride, and placebo was simultaneously compared.

5-ARIs: 5 α -reductase inhibitors; FMPHLSG: Finasteride Male Pattern Hair Loss Study Group; NR: not reported.